lymphoma

Documents about lymphoma

• Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma#18625ClinicalTrials.gov
• Helicobacter Pylori Antibiotic Susceptibility Testing of Korea#121376ClinicalTrials.gov
• Mechanism Investigation of Selinexor Combined With Lenalidomide and Rituximab in the Treatment of Diffuse Large B-cell Lymphoma#123463ClinicalTrials.gov
• Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma#329513ClinicalTrials.gov
• A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular Lymphoma#329540ClinicalTrials.gov
• Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma#329564ClinicalTrials.gov
• Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies#332743ClinicalTrials.gov
• Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant#332758ClinicalTrials.gov
• Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.#343815ClinicalTrials.gov
• A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001#343832ClinicalTrials.gov
• A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma#349946ClinicalTrials.gov
• A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.#349949ClinicalTrials.gov
• Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)#353262ClinicalTrials.gov
• Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma#353343ClinicalTrials.gov
• RCHOP Chemoimmunotherapy Preceded BY BBB Permeabilization by t-NGR Necrosis Factor#356474ClinicalTrials.gov
• Prognosis of lymphoma in patients with known inflammatory bowel disease: A french multicentre cohort study#124350HAL (France)
• Table 1_CORSA study finds spike-specific blunted immune responses in lymphoma patients after SARS-CoV-2 vaccine.docx#202136Figshare
• <b>Curriculum Vitae – Professor Salah Eddine Belakehal, MD | Senior Hematologist, Hospital Executive and Clinical Research Leader</b>#220412Figshare

Related topics